Scilex Holding Co
For the period ended Mar 31, 2026. Filed May 20, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 20, 2026
SCLX$1.61-7.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except for net loss per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Net revenue | $8,613 | $5,004 |
| Net operating costs and expenses: | ||
| Cost of revenue | 4,447 | 1,384 |
| Research and development | 3,210 | 2,456 |
| Selling, general and administrative | 31,033 | 28,060 |
| Intangible amortization | 2,092 | 1,002 |
| Total net operating costs and expenses | 40,782 | 32,902 |
| Loss from operations | (32,169) | (27,898) |
| Other (income) expense, net: | ||
| Gain on warrant derivative liabilities | (25,709) | (10,409) |
| Loss on compound derivative of Scilex-St. James Loans | 21,829 | — |
| Change in fair value of debt and liability instruments | 2,797 | 6,114 |
| Other expense, net | 3,779 | 2,481 |
| (Gain) Loss on foreign currency exchange | 279 | (4) |
| Unrealized loss on digital assets, net | 18,064 | — |
| Unrealized loss on equity method investments carried at fair value, net | 31,710 | — |
| Realized (gain) on equity method investments carried at fair value, net | (42,338) | — |
| Realized loss on securities | 3,071 | — |
| Total other (income) expense, net | 13,481 | (1,818) |
| Loss before income taxes | (45,650) | (26,080) |
| Net loss | (45,650) | (26,080) |
| Net loss attributable to noncontrolling interests | (2,380) | — |
| Net loss attributable to common stockholders | $(43,270) | $(26,080) |
| Loss per share attributable to common stockholders — basic & diluted | $(6.28) | $(2.26) |
| Weighted average number of shares during the period — basic & diluted | 6,891 | 11,565 |
| Comprehensive loss: | ||
| Net loss attributable to common stockholders | $(43,270) | $(26,080) |
| Other comprehensive income: | ||
| Foreign currency translation adjustment | (747) | — |
| Total other comprehensive income | (747) | — |
| Comprehensive loss attributable to common stockholders | $(44,017) | $(26,080) |
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
(In thousands)
| Preferred Stock · Common Stock · Additional · Accumulated Other · Accumulated · Treasury Stock · Noncontrolling · Stockholders’ | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Paid-in Capital | Comprehensive Income | Deficit | Shares | Amount | Interest | Equity (Deficit) | |
| Balance, December 31, 2025 | 34,057 | $1 | 8,491 | $1 | $796,721 | $(5,803) | $(921,786) | 1,458 | $(76,915) | $(3,971) | $(211,752) |
| Acquisition of controlling interest in Vivasor | — | — | — | — | — | — | — | — | — | 1,500 | 1,500 |
| Stock dividend declared in 2024, and canceled in February 2026 | (5,000) | (1) | — | — | 1 | — | — | — | — | — | — |
| Vivasor - secondary purchase | — | — | — | — | (1,050) | — | — | — | — | — | (1,050) |
| Stock-based compensation | — | — | — | — | 3,629 | — | — | — | — | — | 3,629 |
| Other comprehensive income | — | — | — | — | — | (747) | — | — | — | — | (747) |
| Net loss | — | — | — | — | — | — | (43,270) | — | — | (2,380) | (45,650) |
| Balance, March 31, 2026 | 29,057 | $— | 8,491 | $1 | $799,301 | $(6,550) | $(965,056) | 1,458 | $(76,915) | $(4,851) | $(254,070) |
| Preferred Stock · Common Stock · Additional · Accumulated Other · Accumulated · Treasury Stock · Stockholders’ | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Paid-in Capital | Comprehensive Income | Deficit | Shares | Amount | Equity (Deficit) | |
| Balance, December 31, 2024 | 34,057 | $1 | 6,952 | $1 | $454,614 | $6,317 | $(563,052) | 1,716 | $(90,522) | $(192,641) |
| Treasury Stock transferred to Tranche B Investors for Tranche B Notes deferral | — | — | — | — | (5,353) | — | — | (143) | 7,535 | 2,182 |
| Treasury Stock paid for Gloperba Ex-US License | — | — | — | — | (808) | — | — | (22) | 1,174 | 366 |
| Treasury Stock transferred to Oramed for the Oramed Note maturity extension | — | — | — | — | (3,523) | — | — | (93) | 4,898 | 1,375 |
| Stock-based compensation | — | — | — | — | 3,314 | — | — | — | — | 3,314 |
| Net loss | — | — | — | — | — | — | (26,080) | — | — | (26,080) |
| Balance, March 31, 2025 | 34,057 | $1 | 6,952 | $1 | $448,244 | $6,317 | $(589,132) | 1,458 | $(76,915) | $(211,484) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.